Help us: Donate
Follow us on:
×

Journal Club June 2019 – Human Trial Results for Urolithin A

For the June edition of Journal Club, Dr. Oliver Medvedik and guests took a look at the recent human trial of urolithin A, a metabolite produced by microflora and an active ingredient in pomegranates that is linked to increased levels of mitophagy in aged animals.

Urolithin A is a byproduct created when bacteria in the gut break down ellagitannins, which are certain kinds of polyphenols found in fruits such as pomegranates, strawberries, walnuts, and raspberries. The substance does not appear naturally in its end form, so we normally rely on the beneficial bacteria in the microbiome, our internal ecology of gut bacteria, to convert the polyphenols into urolithin A.

Researchers synthesized the urolithin A in the lab and directly gave it to patients, thus bypassing the need to have the particular bacteria that creates it, which some people have and some do not. This reliance on bacteria to create it also explains why some people benefit from eating foods rich in ellagitannins or taking pomegranate supplements and why others gain no benefits. Directly creating urolithin A allows researchers to remove this need to have the bacteria process the urolithin A, which could potentially mean that everyone could enjoy the benefits.

The human trial produced some interesting and promising results, and it seems that this compound may actually delay the mitochondrial dysfunction seen during aging. There are lots of supplements on the market, and it is likely that most of them are absolute junk and snake oil, but there could also be some out there which are useful; urolithin A is looking like it may be.

Literature



Andreux, P. A., Blanco-Bose, W., Ryu, D., Burdet, F., Ibberson, M., Aebischer, P., … & Rinsch, C. (2019). The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism, 1(6), 595.

About the author
Oliver Medvedik

Oliver Medvedik

Oliver Medvedik, Co-founder of Genspace citizen science laboratory in Brooklyn NY, earned his Ph.D. at Harvard Medical School in the Biomedical and Biological Sciences program. As part of his doctoral work he has used single-celled budding yeast as a model system to map the genetic pathways that underlie the processes of aging in more complex organisms, such as humans. Prior to arriving in Boston for his doctoral studies, he has lived most of his life in New York City. He obtained his bachelor’s degree in biology from Hunter College, City University of New York. Since graduating from Harvard, he has worked as a biotechnology consultant, taught molecular biology to numerous undergraduates at Harvard University and mentored two of Harvard’s teams for the international genetically engineered machines competition (IGEM) held annually at M.I.T. Oliver is also the Director of The Maurice Kanbar Center for Biomedical Engineering at the Cooper Union, New York City. The Maurice Kanbar Center for Biomedical Engineering is open to all Cooper Union faculty and students working on bioengineering projects requiring equipment and space for tissue culture, genetic engineering, biomechanics, and related research. Faculty that is currently using the facility are pursuing groundbreaking biomedical research in such fields as biomedical devices, tissue engineering, obstructive sleep apnea biomechanics also collaborating with several major New York City-based hospitals. The Kanbar Center continues to provide space for undergraduate teams participating in the international genetically engineered competition (iGEM) during the summer, as well as space for courses that offer a biological laboratory component.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You have 3 free articles remaining this week. You can register for free to continue enjoying the best in rejuvenation biotechnology news. Already registered? Login here.